Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XOMA 052 |
Synonyms | |
Therapy Description |
XOMA 052 (gevokizumab) is a monoclonal antibody that targets interleukin-1 beta (IL1B) and reduces the binding affinity of IL1B to IL1R1 and IL-1RAcP receptors, potentially resulting in decreased inflammatory response and reduced ILB1 signaling (PMID: 20410301, PMID: 24194526, PMID: 21048425). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XOMA 052 | Gevokizumab|VPM087 | XOMA 052 (gevokizumab) is a monoclonal antibody that targets interleukin-1 beta (IL1B) and reduces the binding affinity of IL1B to IL1R1 and IL-1RAcP receptors, potentially resulting in decreased inflammatory response and reduced ILB1 signaling (PMID: 20410301, PMID: 24194526, PMID: 21048425). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05178576 | Phase II | XOMA 052 | A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy | Withdrawn | USA | 0 |